ResMed forward PE RMD

Share price divided by analysts' consensus earnings for the next twelve months, since 1996.

Today, Oct 23, 2026: 20.8×
10-year median: 29.1×
Against its 10-year history: 9th; percentile: 0 is its lowest day, 100 its highest
10-year range: 16.0× to 51.3×
Peer median: 30.4×

ResMed's forward PE is 20.8× as of Oct 23, 2026.

That is below its ten-year median of 29.1×, lower than on 91% of days in the last ten years.

Over that time it ranged from 16.0× in Jun 2026 to 51.3× in Sep 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 30.4×.

Forward PE over time

median 29.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	20.8×	16.0×	23.8×
2025	22.0×	20.2×	26.8×
2024	24.0×	20.8×	26.9×
2023	21.9×	17.2×	36.0×
2022	31.9×	31.8×	43.2×
2021	43.9×	33.5×	51.3×
2020	40.6×	25.9×	43.3×
2019	37.6×	25.8×	37.6×
2018	31.7×	26.7×	33.7×
2017	25.8×	22.4×	26.6×
2016	22.4×	19.2×	25.4×
2015	19.8×	19.1×	29.7×
2014	23.3×	17.7×	23.3×
2013	18.6×	18.2×	22.0×
2012	18.9×	16.3×	20.3×
2011	16.6×	16.2×	24.8×
2010	25.3×	23.3×	27.5×
2009	24.9×	18.4×	25.5×
2008	21.3×	19.4×	33.5×
2007	35.5×	26.8×	35.9×

Against its peers

Companies in Medical - Instruments & Supplies nearest ResMed's size, closest first, today.

Company	Forward PE
RMDResMed	20.8×
MDLNMedline	23.2×
WSTWest Pharmaceutical Services	42.2×
BDXBecton, Dickinson and	15.1×
SOLVSolventum	n/m
PENPenumbra	n/m
COOCooper Companies	n/m
ALGNAlign Technology	n/m
GMEDGlobus Medical	n/m
PODDInsulet	n/m
ISRGIntuitive Surgical	37.5×
Peer median	30.4×

Where ResMed ranks

#30of 51Healthcare stocks with the lowest forward PE

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on ResMed

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.